Influx Healthtech shares list at 38% premium over IPO price on NSE SME

Healthcare-focused contract manufacturer Influx Healthtech made a strong debut on the NSE SME platform today, listing at Rs 132.5 per share, a 38% premium over its IPO price of Rs 96.

The Rs 58.57 crore IPO had closed for subscription on June 20.

Ahead of the listing, the grey market premium (GMP) for Influx Healthtech stood at around Rs 20, implying an expected listing price of Rs 116 — a potential gain of 20.83%. However, the stock surpassed grey market expectations with a significantly stronger opening.

IPO Overview

The IPO comprised a fresh issue of 50 lakh shares worth Rs 48 crore and an offer for sale (OFS) of 11 lakh shares worth Rs 10.56 crore, offering a total of 61,00,800 shares. The IPO price was fixed at Rs 96 per share.

The anchor portion attracted Rs 16.67 crore, with shares allocated to institutional investors a day before the issue opened.

Company background

Established in 2020, Influx Healthtech is a CDMO (Contract Development and Manufacturing Organization) providing end-to-end manufacturing and product development services for nutraceuticals, cosmetics, personal care, ayurvedic, veterinary, and homecare products.

Operating out of three modern facilities in Thane, Maharashtra, the company boasts an extensive portfolio including gummies, capsules, powders, skincare products, herbal supplements, and veterinary feed formulations. It serves nutraceutical, cosmetic, and healthcare clients, handling everything from formulation and R&D to regulatory support and packaging.

The company currently employs 163 people and continues to expand its product capabilities and client reach, focusing on innovation and scalability in fast-growing consumer health segments.

Financials and Valuation

Influx Healthtech posted a revenue of Rs 104.99 crore in FY25, up 5% year-on-year, while PAT rose 19% to Rs 13.37 crore. It maintains a robust ROE of 36.98%, EBITDA margin of 19.62%, and negligible debt.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)